✦ LIBER ✦

Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma

✍ Scribed by H. Bier; K. A. Reiffen; I. Haas; P. Stasiecki

Book ID: 112275103
Publisher: Springer-Verlag
Year: 1995
Tongue: English
Weight: 598 KB
Volume: 252
Category: Article
ISSN: 0302-9530
DOI: 10.1007/bf00167315

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I Pharmacokinetic and Pharmacodyna

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

✍ Paz-Ares, L. G.; Gomez-Roca, C.; Delord, J.-P.; Cervantes, A.; Markman, B.; Corr 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 192 KB

Clinical trial with escalating doses of

Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx

✍ Henning Bier; Thomas Hoffmann; Ulrich Hauser; Michael Wink; Martin Öchler; Andre 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 99 KB